1342. Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates

BACKGROUND: CF-301 (exebacase) is a novel, recombinantly produced, bacteriophage-derived lysin (cell wall hydrolase) which is the first lysin to enter Phase 2 (Ph2) in the United States and is being studied for the treatment of S. aureus bacteremia including endocarditis. We examined the activity of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Anastasiou, Diane, Jandourek, Alena, Traczewski, Maria, Cassino, Cara, Schuch, Raymond
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6253852/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1173
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky